miRecule, a biotechnology company developing RNA-based therapies, has announced a new strategic partnership with GBI Biomanufacturing, a contract development and manufacturing organisation (CDMO), to accelerate the development and clinical supply of its innovative Antibody-RNA Conjugate (ARC) therapies. The collaboration aims
GBI Biomanufacturing (GBI), a contract development and manufacturing organisation (CDMO), has expanded its Drug Product (DP) services by adding automated sterile fill-finish capabilities at its facility in Florida, USA. This development enhances GBI’s ability to provide end-to-end manufacturing solutions for
GBI Biomanufacturing, a contract development and manufacturing organization (CDMO), has entered a partnership with Allterum Therapeutics to produce Allterum’s lead cancer therapy candidate, 4A10. The monoclonal antibody (mAb), which targets CD127, will be manufactured for Phase 1/2a clinical trials. The
GBI Biomanufacturing is a company operating in the pharmaceutical industry. GBI (formerly Goodwin Biotechnology) is based in the USA (Florida) and has 30 years of recombinant protein, antibody, bioconjugates, and exosome manufacturing experience. We are FDA registered (including PAI approval),
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
